GALT Galectin Therapeutics Inc
Price (delayed)
$1.32
Market cap
$83.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.76
Enterprise value
$174.5M
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin (formerly known as GR-MD-02) is a
Highlights
Galectin Therapeutics's quick ratio has shrunk by 74% YoY and by 60% QoQ
GALT's equity has dropped by 69% year-on-year and by 11% since the previous quarter
Key stats
What are the main financial stats of GALT
Market
Valuations
Earnings
Shares outstanding
63.18M
Market cap
$83.4M
Enterprise value
$174.5M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$42.43M
Net income
-$47.05M
EBIT
-$41.51M
EBITDA
-$41.47M
Free cash flow
-$41.77M
Per share
Balance sheet
Liquidity
EPS
-$0.76
EPS diluted
-$0.76
Free cash flow per share
-$0.67
Book value per share
-$1.67
Revenue per share
$0
TBVPS
$0.28
Total assets
$17.5M
Total liabilities
$120.57M
Debt
$106.23M
Equity
-$104.79M
Working capital
-$18.16M
Debt to equity
-1.01
Current ratio
0.49
Quick ratio
0.43
Net debt/EBITDA
-2.2
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-188.8%
Return on equity
N/A
Return on invested capital
-54%
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GALT stock price
How has the Galectin Therapeutics stock price performed over time
Intraday
4.76%
1 week
-19.51%
1 month
-15.92%
1 year
-47.41%
YTD
2.33%
QTD
8.2%
Financial performance
How have Galectin Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$42.43M
Net income
-$47.05M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 11% year-on-year and by 7% since the previous quarter
The company's net income fell by 5% YoY and by 4.4% QoQ
Growth
What is Galectin Therapeutics's growth rate over time
Valuation
What is Galectin Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Galectin Therapeutics's EPS has decreased by 4.1% QoQ and by 2.7% YoY
GALT's equity has dropped by 69% year-on-year and by 11% since the previous quarter
Efficiency
How efficient is Galectin Therapeutics business performance
GALT's ROIC is up by 34% YoY and by 2.2% QoQ
The ROA has contracted by 16% from the previous quarter but it has grown by 4.5% YoY
Dividends
What is GALT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GALT.
Financial health
How did Galectin Therapeutics financials performed over time
Galectin Therapeutics's total assets is 85% less than its total liabilities
Galectin Therapeutics's quick ratio has shrunk by 74% YoY and by 60% QoQ
GALT's current ratio has shrunk by 72% YoY and by 57% QoQ
GALT's equity has dropped by 69% year-on-year and by 11% since the previous quarter
The debt has grown by 48% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.